Here’s what you need to know:
1. Patients who have a current or previous hepatitis B virus infection, and who are being treated with one of these medications (such as Daklinza, Epclusa or Harvoni, among others), are at risk of hepatitis B reactivation.
2. Some patients’ whose hepatitis B infection had reactivated after hepatitis C treatment experienced serious liver problems — or even death.
3. The FDA has required their most prominent warning, a “boxed warning,” about the risk of hepatitis B reactivation to be added to the drug labels of these hepatitis C medications.
4. The FDA says that healthcare professionals should screen and monitor all patients for current or previous hepatitis B infection prior to starting treatment with hepatitis C medication.
5. It is still unknown why the hepatitis B reactivation occurs.
More articles on quality and infection control:
3 key thoughts on growing a hygiene improvement business
This peptide may treat bacterial infections: 3 study insights
Healthmark adds single-use gown to product line: 3 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
